← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Aug 29, 2026

ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Healthcare • NASDAQ

$84.91

Arrowhead Pharmaceuticals Inc. is an American biotechnology company headquartered in Pasadena, California, that develops RNA interference (RNAi) therapeutics targeting genetic disease. The company's proprietary TRiM (Targeted RNAi Molecule) platform delivers subcutaneous or inhaled RNA therapeutics to the liver, lung, and other tissues, with plozasiran (for severe hypertriglyceridemia) and other programs targeting cardiometabolic and liver diseases.

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

44.0/100

WEAK BUSINESS

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) scores 44/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full ARWR quality analysis & detailed breakdown

VALUATION SIGNAL

MARGIN OF SAFETY

Is this stock cheap or expensive relative to what the business has historically generated for owners?

-100.0%

Overvalued

Growth gap unavailable — insufficient data for reverse DCF calculation.

🎯 Expected Annual Return →

-47.8%

Margin of Safety convergence — your return if the market re-prices to intrinsic value (5-yr annualised)

2.7%

Yield + growth — what the business alone earns you, even if the market never re-rates

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full ARWR valuation analysis · → View full ARWR Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-60.1%)

Debt-to-Equity (Solvency Risk):GOOD (0.51x)

Operating Margin (Operational Efficiency):CRITICAL (-52.3%)

Return on Capital (Capital Efficiency):CRITICAL (-29.0%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) stock report — Zyberno Score 44/100 (WEAK BUSINESS), Margin of Safety -100.0%, -48% expected annual return. Full financial analysis on Zyberno.

According to Zyberno's DCF model, ARROWHEAD PHARMACEUTICALS, INC. (ARWR) trades at $84.91 against an estimated intrinsic value per share of $10.06 — a -100.0% Margin of Safety based on Owner Earnings of $323.50M TTM, projected at -23.7% growth for 10 years with a 2.5% terminal growth rate. Zyberno's model translates this into a 5-year expected return of -47.8% annually.

Over the trailing twelve months, ARWR generated $323.50M in Owner Earnings. Capital was deployed as follows: $17.30M invested in capital expenditures. Reinvestment rate: -0.3%. Owner Earnings have declined at 23.7% annually over the trailing five years using log-linear regression.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:84.91

Market Cap:$12.17B

Valuation Multiples (3)

P/B Ratio:26.12x

P/S Ratio:28.10x

Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$12.29B

Pfcf Ratio:37.81x

Price Action & Momentum (3)

12-1 Momentum:

+441.8% (99th pctile)

📈 Click to view full ARWR Momentum analysis →

Momentum Percentile:99 / 100

% of 52-Week High:88.9%

B. Profitability Assessment

Return Metrics (5)

ROE:

-60.1%

📊 Click to view full ARWR ROE analysis →

ROA:-17.4%

Roic:

-29.0%

📊 Click to view full ARWR ROIC analysis →

Reinvestment Rate:-0.3%

Fundamental Growth Rate (g):0.1%

Margin Analysis (3)

Operating Margin Ttm:-52.3%

Net Margin Ttm:-73.9%

Ebitda Margin:-46.7%

TTM Performance (2)

Operating Margin Ttm:-52.3%

Net Margin Ttm:-73.9%

Yield Metrics (3)

Earnings Yield:-$2.57

Owner Earnings Yield:$2.66

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

Earnings Surprise (SUE):

-0.03

📊 Click to view full ARWR Earnings Surprise analysis →

EPS Surprise vs Expected:-2.9%

Latest Earnings Filed:2026-08-04

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):15.9%

Cash Flow Growth (Linear) (2)

Free Cash Flow Growth Rate (Linear):-23.7%

Operating Cash Flow Growth Rate (Linear):-19.9%

Operating Growth (Linear) (1)

Operating Income Growth Rate (Linear):3.7%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:5.90x

Quick Ratio:5.90x

Cash Ratio:0.00x

Leverage Analysis (3)

Debt To Equity Ttm:0.51x

Debt-to-Equity Ratio:0.51x

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:1.06x

Times Interest Earned:1.06

Capital Structure (4)

Working Capital:1,388,065,000.00

Cash And Cash Equivalents:0.00

Long Term Debt:$114.30M

Net Debt:$119.62M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $433.23M

Linear Growth: 15.9%

📊 Click to view full ARWR Revenue analysis & methodology →

Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00

Operating income TTM: -$226.44M

Linear Growth: 3.7%

📊 Click to view full ARWR Operating Income analysis & methodology →

Bottom Line Performance (3)

-$319.95M

Income Before Tax:-$252.08M

Ebitda Ttm:-202,338,000.00

Operating Expenses (5)

Operating Expenses:895,933,000.00

R And D Expense:723,366,000.00

Sga Expense:172,567,000.00

Income Tax Expense:$20.05M

Interest Expense:92,607,000.00

Expense Ratios (3)

R And D To Revenue Percentage:961.2%

Sga To Revenue Percentage:229.3%

Ebitda Margin:-46.7%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$2.11B

Current Assets:$1.67B

Ppe Net:373,301,000.00

Goodwill:0.00

Intangible Assets:$5.59M

Liability Structure (4)

Total Liabilities:1,645,972,000.00

Current Liabilities:283,346,000.00

Long Term Debt:$114.30M

Short Term Debt:$5.32M

Equity & Capital (3)

Equity:$466.04M

Retained Earnings:-$1.92B

Common Stock:290,000,000.00

Working Capital Items (3)

Accounts Receivable:8,556,000.00

Inventory:0.00

Accounts Payable:86,174,000.00

Special Items (2)

Contract Liabilities:94,596,000.00

Stock Based Compensation:14,974,000.00

C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: $339.31M

Linear Growth: -19.9%

Free cash flow TTM: $322.01M

Linear Growth: -23.7%

📊 Click to view full ARWR Free Cash Flow analysis & methodology →

Investment Activities (2)

Investing Cash Flow:-$23.74M

Capital Expenditures Ttm:17,298,000.00

Financing Activities (3)

Financing Cash Flow:-$14.75M

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:46,832,000.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:24,100,000.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-2.21

-$2.18

Earnings Per Share Ttm:-$2.23

Revenue & Cash Per Share (3)

Sales Per Share Ttm:3.02

Operating Cash Flow Per Share:$1.25

Fcf Per Share Ttm:2.25

Book Value & Capital (2)

Book Value Per Share:$3.25

Cash Per Share:-999.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.24x

Working Capital Turnover Ttm:0.31x

Receivables Management (2)

Receivables Turnover Ttm:50.63x

Days Sales Outstanding Ttm:7.21

Inventory Management (2)

Inventory Turnover Ttm:-999.00x

Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:72.60

Cash Conversion Cycle:-1,064.39

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00

Quality Score:55.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Owner Earnings Analysis (3)

Owner earnings TTM: $323.50M

Linear Growth: -23.7%

📊 Click to view full ARWR Owner Earnings analysis & methodology →

Owner Earnings Per Share:$2.26

Owner Earnings Yield:$2.66

Growth Assessment (1)

Owner Earnings Growth Rate:-$23.70

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.3%

Fundamental Growth Rate (g):0.1%

Intrinsic Value Models (1)

Intrinsic Value:

$1.44B

📊 Click to view full ARWR DCF valuation →

Margin of Safety (1)

Margin Of Safety:

-100.0%

📊 Click to view full ARWR valuation analysis →

Return Scenarios (2)

Theoretical 5-Year Return:

-47.8%

📊 Click to view full ARWR expected return analysis →

Forward Expected Return (Yield + Growth):

2.7%

📊 Click to view full ARWR expected return analysis →

Investment Assessment (1)

Buffett Assessment:Overvalued

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (2)

Revenue Growth Rate (Linear):15.9%

Operating Income Growth Rate (Linear):3.7%

Cash Flow Growth Rates (2)

Free Cash Flow Growth Rate (Linear):-23.7%

Operating Cash Flow Growth Rate (Linear):-19.9%

Other Growth Rates (2)

Book Value Growth Rate (Linear):7.8%

Owner Earnings Growth Rate:-$23.70

C. Company Profile & Context

Corporate Information (6)

Symbol:ARWR

Company Name:ARROWHEAD PHARMACEUTICALS, INC.

Sector:Healthcare

Industry:Pharmaceuticals

Exchange:NASDAQ

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:high

Volume Category:N/A

Share Structure (3)

Shares Outstanding:143.38M

Shares Outstanding Basic:143.38M

Shares Outstanding Diluted:143.38M

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-08-29 13:30:57 UTC

Data Timestamp:2026-08-29T13:30:57.460145